Inspire Investing LLC Has $798,000 Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Inspire Investing LLC lifted its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 13.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,798 shares of the specialty pharmaceutical company’s stock after buying an additional 2,917 shares during the quarter. Inspire Investing LLC owned about 0.08% of Collegium Pharmaceutical worth $798,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Gladius Capital Management LP bought a new stake in Collegium Pharmaceutical in the second quarter valued at approximately $32,000. Principal Securities Inc. acquired a new stake in Collegium Pharmaceutical during the 4th quarter valued at $40,000. nVerses Capital LLC boosted its position in Collegium Pharmaceutical by 1,600.0% during the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 1,600 shares during the period. Assetmark Inc. increased its holdings in shares of Collegium Pharmaceutical by 25.5% in the fourth quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock valued at $168,000 after purchasing an additional 1,108 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC bought a new position in shares of Collegium Pharmaceutical in the first quarter valued at about $204,000.

Insider Activity

In related news, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares in the company, valued at approximately $1,970,741.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the transaction, the executive vice president now owns 120,161 shares of the company’s stock, valued at $4,602,166.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Thomas B. Smith sold 9,593 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the sale, the executive vice president now owns 53,816 shares in the company, valued at $1,970,741.92. The disclosure for this sale can be found here. Corporate insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $39.07 on Friday. The firm has a market cap of $1.28 billion, a PE ratio of 16.28 and a beta of 0.94. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.11 and a quick ratio of 1.04. The stock’s fifty day moving average price is $36.09 and its two-hundred day moving average price is $35.47. Collegium Pharmaceutical, Inc. has a one year low of $20.95 and a one year high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The company had revenue of $145.28 million for the quarter, compared to analysts’ expectations of $143.94 million. During the same quarter last year, the business earned $1.13 earnings per share. Collegium Pharmaceutical’s revenue was up 7.2% on a year-over-year basis. As a group, research analysts expect that Collegium Pharmaceutical, Inc. will post 5.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on COLL shares. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 31st. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Piper Sandler restated a “neutral” rating and issued a $37.00 price target (down from $39.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. HC Wainwright increased their price objective on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. Finally, Jefferies Financial Group raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and lifted their target price for the stock from $41.00 to $44.00 in a report on Friday, June 7th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.